Dr Porter on Community-Based CAR T-Cell Therapy Administration for R/R CLL
David L. Porter, MD, discusses the utility of CAR T-cell therapy in the community setting for relapsed/refractory chronic lymphocytic leukemia.
Source: onclive.com
Davidl Porter News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Davidl Porter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Davidl Porter Today - Breaking & Trending Today
CAR T-Cell Therapy Makes its Mark in CLL
David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.
Source: onclive.com
New COVID-19 variants have 'major impact' on prevention for cancer cell therapy recipients
The FDA recently withdrew its emergency use authorization for Evusheld, a combination monoclonal antibody therapy used to prevent COVID-19 among high-risk individuals.The agency revised guidance on emergency use of Evusheld (tixagevimab plus cilgavimab, AstraZeneca) to when the combined national frequency of variants not susceptible to the treatment is 90% or less.
Source: healio.com